Register entry
TWi Pharmaceuticals, Inc.
- Registered sites
- 1
- Drug products
- 3
- Live patents
- 1
- Countries
- 1
- Base
- Taiwan
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testing
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| TWi Pharmaceuticals, Inc. | Taipei CityTaiwan | Analytical testing | 3008317961 |
Exclusivity
Patents
1Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| FORFIVO XL | BUPROPION HYDROCHLORIDE | Aug 2028 |
Catalogue
Marketed products
3Showing 3 of 3.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| Guanfacine Hydrochloride | Guanfacine | TABLET | ANDA |
| Guanfacine Hydrochloride | Guanfacine | TABLET | ANDA |
| Sevelamer Carbonate | Sevelamer Carbonate | TABLET, FILM COATED | ANDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.